Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
OCUL - Ocular Therapeutix, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$27.50
DETAILS
HIGH:
$30.00
LOW:
$25.00
MEDIAN:
$27.50
CONSENSUS:
$27.50
UPSIDE:
155.10%
Stock News
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Beth Rada, the Company's new SVP, Government Affairs and Public Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
California State Teachers Retirement System Increases Stock Position in Ocular Therapeutix, Inc. $OCUL
California State Teachers Retirement System increased its holdings in Ocular Therapeutix, Inc. (NASDAQ: OCUL) by 41.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 213,706 shares of the biopharmaceutical company's stock after acquiring an additional 63,005 shares during the quarter. California
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees.
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat
Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked regulatory path and strong Phase 3 efficacy data. AXPAXLI's annual dosing and clinic productivity benefits could drive adoption beyond wet AMD, targeting broader retinal indications including diabetic retinopathy. The FDA has agreed to an NDA submission in Q4 2026 based on SOL-1 data and interim safety from SOL-R, reducing near-term regulatory risk.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on the planned filing package.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive employees.
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
BEDFORD, Mass. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026. Upcoming Scientific Conferences: 9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026Montréal, Quebec Presentation: Ocular Therapeutix: Retina Experience RedefinedPresentation Date/Time: Tuesday, July 14, 2026, 11:37 - 11:44 AM EDTPresenter: Peter K.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company's new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares for its Investor Day, where it will detail its plans for submitting a New Drug Application (NDA) for AXPAXLI.
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DNA technology to search and replace genetic mutations at their source.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to seven newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M.
Price Targets
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
$25.00
(was $9.44)
H.C. Wainwright
Ocular Therapeutix price target raised to $30 from $24 at Baird
$30.00
(was $9.64)
Robert W. Baird
RBC Capital on Ocular Therapeutix (OCUL): Weakness a Buying Opportunity
$30.00
(was $9.29)
Lisa Walter
·
RBC Capital
Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright
$21.00
(was $12.58)
H.C. Wainwright
Ocular Therapeutix price target raised to $19 from $15 at H.C. Wainwright
$19.00
(was $11.52)
H.C. Wainwright
Ocular Therapeutix price target raised to $31 from $21 at Piper Sandler
$31.00
(was $11.06)
Piper Sandler
Ocular Therapeutix price target raised to $24 from $17 at Baird
$24.00
(was $11.06)
Colleen Kusy
·
Robert W. Baird
Ocular Therapeutix price target raised to $29 from $20 at Citizens JMP
$29.00
(was $11.69)
Jonathan Wolleben
·
JMP Securities
Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness
$19.00
(was $6.50)
JMP Securities
Ocular Therapeutix price target lowered to $17 from $18 at Baird
$17.00
(was $8.37)
Colleen Kusy
·
Robert W. Baird
Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)
$15.00
(was $6.71)
Biren Amin
·
Piper Sandler
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
$14.00
(was $5.89)
Yi Chen
·
H.C. Wainwright
Ocular Therapeutix (OCUL) PT Raised to $24 at JMP Securities
$24.00
(was $9.29)
Jonathan Wolleben
·
JMP Securities
Ocular Therapeutix (OCUL) Stock Price: $10 Target And Overweight Rating
$10.00
(was $3.78)
Joseph Catanzaro
·
Piper Sandler